MAPK3 and ovarian cancer: In ovarian cancer, DUSP6 expression is lost, particularly at the protein level, leading to the hyperactivation of ERK1/2 and eventually resulting in tumorigenicity and chemoresistance of human ovarian cancer cells (17).